A novel vaccine with proprietary intellectual property, developed using a CHO cell expression system and a novel adjuvant. Preclinical studies have demonstrated promising immunogenicity and safety profiles, and the vaccine is currently in the preclinical research phase.

As a leading manufacturer of the first HPV vaccine brand in developing countries, Innovax continues to advance innovation in cervical cancer prevention. Leveraging structural vaccinology, Innovax has independently designed a multi-valent chimeric epitope HPV vaccine with broad-spectrum protection. This unique "one-against-multi" formulation aims to provide over 99% preventive efficacy against HPV-related diseases. The vaccine is currently in the preclinical development stage.

In February 2021, Innovax licensed the 20-valent pneumococcal polysaccharide-protein conjugate vaccine technology from Jiangsu Kunli Biopharmaceutical Co., Ltd.. Clinical trial approval was obtained in September 2021, and the Phase 1 clinical trial is currently progressing as planned. All study cohorts completed enrollment by February 2024, with final patient follow-ups scheduled to commence after December 2024.